Berlex Recalls One Lot Of Contrast Agent Ultravist
This article was originally published in The Pink Sheet Daily
Executive Summary
Berlex will credit customers for the 650 recalled infusion bottles of the intravenous x-ray contrast agent Ultravist already distributed into the market, the firm told "The Pink Sheet" DAILY
You may also be interested in...
Schering AG To Continue Leukine Development In Wake Of Disappointing Phase III Trial
Bayer offer to purchase Schering AG stands despite trial setbacks and expansion of Ultravist recall.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.